Communication

Initial Effects of the SB Natural Anticancer Drug on the Number of NK Cells, CD4+ and CD8+ T Lymphocytes in Human Peripheral Blood

Jong-Hwa Lee1,2, Yoo-Jin Cho1,2, Myung-Sup Chae3, Wang-Jae Lee4, U-Hyun Park5,6, Euishin Edmund Kim5,7,8,*

1Department of Internal Medicine, Sahmyook Cancer Center, Sahmyook Seoul Hospital, Seoul, Korea
2Department of Internal Medicine, Sahmyook Seoul Hospital, Seoul, Korea
3Department of Family Medicine, Sahmyook Seoul Hospital, Seoul, Korea
4Department of Anatomy, College of Medicine, Seoul National University, Seoul, Korea
5Department of Medical Oncology, Kyunghee University Hospital, Seoul, Korea
6Department of Internal Medicine, East-West Integrative Medicine Hospital, Wien, Austria
7Department of Molecular Medicine, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea
8Department of Radiological Sciences, University of California Medical Center, Irvine, USA

Email address: eedkim@yahoo.com (E. E. Kim)

*Corresponding author

To cite this article:

Received: May 24, 2018; Accepted: July 19, 2018; Published: August 14, 2018

Abstract: Most anticancer drugs produce cytotoxicities in cancer cells, but also generate effects in normal cells that create undesirable side effects, especially for immune functioning cells which have already been suppressed by cancer invasion or biological effects. The SB natural anticancer drug is a root extract of the Pulsatilla koreana plant that has been used in Korea as an effective anticancer agent for more than 20 different malignant tumors without triggering significant adverse reactions. We investigated the effects of the SB anticancer drug on human immune cells in cancer patients. 24 consecutive patients, with histologically proven cancers, received SB drug treatments and 20 control patients did not receive SB administrations. Both groups were immunologically tested before and after their SB treatments for 14 days and then weekly for the 3rd, 4th, 5th and 6th weeks thereafter. The total number of white blood cells with differential counts including monocytes and lymphocytes were checked. Immunoassay and flow cytometry were used to analyse CD4 and CD8 T cell percentages, total cell counts with their ratios, as well as CD16/56 natural killer cell percentages and cell counts. Total white blood cell counts normalized within 10 days after the SB drug administrations. The total lymphocyte counts were slightly increased, but remained within normal parameters. CD4 and CD8 T cells, as well as CD 16/56 NK cell percentages, became normal within 10 days; their total cell counts were initially increased (26.3%, 45.2%, and 16.7%, respectively) and then became normal. The SB drug was found to be effective cytoapoptotically and was also effective for immune cell recovery in cancer patients in their initial period of the SB drug treatment. These were patients who had already had a bone marrow suppression by cancer invasion and/or prior chemotherapy.

Keywords: Initial Effects, The SB Natural Anticancer Drug, NK Cells, CD4+ and CD8+ T Lymphocytes, Human Peripheral Blood
1. Introduction

In advanced cancer treatments, anticancer drugs have commonly been used for more than half of century until now. Most of anticancer drugs impact their cytotoxicities, not only on cancer cells, but also on normal cells. This causes undesirable toxic side effects, especially on immune functioning cells. The patient’s immunity is generally impaired by the bone marrow suppression caused by cancer cell invasion, resulting in severe infections and rapid cancer dissemination [1, 2].

A T cell is a type of lymphocyte that plays a central role in cell-mediated immunity. T cells mature in the thymus from thymocytes. Eventually they have one of two distinct phenotypes on their surface: CD4 or CD8. CD4 T cells are generally called “Helper T cells” (Th) that send helpful signals to produce antibody production in other types of lymphocytes, like B lymphocytes, which play a key role in antibody production. There are many subsets in CD4 T cells, such as Th1, Th2, Th17 cells, follicular helper T (Thf) cells and even regulatory T (Treg) cells. Their functions are so diverse that they are stimulatory in some cases, while being inhibitory in others. CD8 T cells are also called cytotoxic T cells. These have killer functions for virus-infected or tumor cells.

The CD4/CD8 ratio measures the ratio of T helper cells to cytotoxic cells. The ratio in healthy adults is 2:3. Although it must be said that the ratio itself has limited value because of the functional diversity of CD4 T cells among several distinct subsets. The ratio does, however, roughly reflect the immune status of each individual. The altered ratio can actually indicate diseases relating to immune deficiency or autoimmunity. For example, an inverted ratio, namely less than two, might indicate an impaired immune system. A reduced ratio is associated with a decreased resistance to infection. A high ratio is associated with patient survival as in non-small cell lung cancer [3].

The SB natural anticancer drug is a root extract of Pulsatilla koreana and has been used in Korea more than 20 years as an effective anticancer agent for various kinds of malignancies without significant toxicities in many preclinical and clinical trials [4-7]. Its apoptotic Pulsatilla saponin D fraction [8], and antiangiogenic, as well as immune potentiative deoxypodophyllotoxin components [9] have been well reported.

We investigated the effects of the SB anticancer drug on human immune functioning cells after treating them by intravenous and percutaneous direct intratumoral injections in advanced cancer patients.

2. Methods and Materials

Patient selection took place between April 2014 and September 2014. 24 consecutive advanced and recurrent cancer patients, who had been diagnosed histologically, were admitted to Sahmyook Seoul Hospital for SB anticancer drug treatment. There were also 20 control patients in the same hospital during the same period who did not receive SB anticancer treatments. The performance status was 3-4, an absolute granulocyte >1,500/µL, hemoglobin level >10g/dL, platelet count > 50,000 /µL and adequate renal and hepatic function, creatinine and bilirubin<1.5x upper limit of normal (ULN), AST and ALT <2.0x ULN. Exclusion criteria included concurrent other malignancies and serious medical conditions that would impair the ability of the patient to receive protocol treatment. Venous bloods were collected from each patient for immunological tests on scheduled days before and after the SB drug administrations during the first 14 days and then weekly for the 3rd, 4th, 5th and 6th weeks thereafter.

Informed consent was obtained from all individual participants in our study. All procedures performed in our study were in accordance with the ethical standards of the institutional research committee and with 1964 Helsinki declaration.

Assessment of data Total white blood cell counts with differential counts including monocytes and lymphocyte were analyzed. CD4, CD8 T cell and CD16/56 natural killer cell percentages, as well as total cell counts, were obtained by immunoassay using the fluorochrome conjugated monoclonal antibody for CD4, CD8 and CD16/56 antigen counting and using flow cytometry.

Statistical Analysis All statistical analyses were performed with SPSS software (version Chicago, IL USA) and a p-value less than 0.05 were considered statistically significant.

3. Results

Total white blood cell counts (normal range: 4,100-10,200/µL) 8,798.5±7,931.4/µL, increased in 5 patients (20.8%) and decreased in one patient (4.2%) before the SB administrations. After the SB administrations they had 8,471.0±3,508.8/µL, increased in 3 patients (12.5%) and decreased in one patient (4.2%). They were normal within 10 days (Figure 1). Monocyte counts (normal range: 0-1,200) were 763.1/µL on average and increased in 2 patients before SB administrations. They were decreased to 562.5/µL after SB administrations. In the control group they decreased from 991.4/µL to 459.9/µL.

Total lymphocyte counts (normal range: 460-5,100/µL) were 1,334.0/µL on average, and increased to 2,997.7/µL after the SB administrations, but remained within normal ranges (Figure 1). CD4 T cell percentages (normal range: 29-57%) were 40.3% on average before SB administrations. They increased in one patient (4.2%) and decreased in 4 patients (16.6%) with 577.6 ±434.3/µL of total cell counts on average (normal range: 750-820/µL). In the control group the cell counts also decreased to 522.8±189.5/µL. After SB administrations, the CD4 T cell percentage was 38.6% on average. It increased in two patients (8.3%) but decreased in 5 patients (20.8%), whose counts were increased to
In the control group they decreased to 212.0±220.6/µL (Figure 2). Before SB administration, the CD8 T cell percentage (normal range: 11-38%) was 27.2% on average. This increased in two patients (8.3%), decreased in two patients (8.3%), and total cell counts (normal range: 450-500/µL) were found to be 396.4±348.9/µL in SB patients and 403.3±321.3/µL in control group. After the SB administrations, the CD8 T cell percentage was 34.9% on average. It increased in 8 patients (33.3%) who were normal within 10 days with 574.9±430.3/µL of total cell counts. This was a significant increase of (45.2%, p<0.05) that is 20.1% above normal. However, in the control group the CD8 T cell counts were markedly decreased to 113.4±148.4/µL (Figure 3). The CD4/CD8 ratio (normal range: 1.71-1.92) was 1.60 on average in the SB treatment patients and 1.47 in the control group before SB administration. After SB administration the average ratio was 1.33 in SB patients and increased markedly to 4.54 in the control group.

The CD16/56 natural killer (NK) cell percentage (normal range: 5-35%) was 15.3% on average in SB patients, and increased in two patients (8.3%) while it decreased in one patient (4.2%) before SB administration. Total cell counts (normal range: 280-320/µL) were 270.8±196.7/µL in patients who received SB treatment and 397.8±288.0/µL in the control group. After SB administration, the CD16/56 NK cell percentage was on average (21.4%), and decreased in two patients (8.3%), but normalized 3 days later, with a total cell count (316.1±169.1/µL) (16.7% increments). The immune system was boosted by an increment of 16.7%. In the control group it was, however markedly decreased to a cell count of 186.2±257.1/µL (Figure 4).

### Table 1. Characteristics of enrolled patients.

<table>
<thead>
<tr>
<th>Variables</th>
<th>SB Treated Group</th>
<th>Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of cases</td>
<td>24</td>
<td>20</td>
</tr>
<tr>
<td>Age range (yrs.)</td>
<td>27-80 (median: 56.5)</td>
<td>35-79 (median: 59.5)</td>
</tr>
<tr>
<td>Male</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Female</td>
<td>16</td>
<td>12</td>
</tr>
<tr>
<td>Lung ca.</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Pancreas ca.</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>Liver ca.</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Biliary ca.</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Stomach ca.</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Colon ca.</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Ovary ca.</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Performance scale</td>
<td>3-4</td>
<td>3-4</td>
</tr>
</tbody>
</table>

Figure 1. The changes of white blood cell counts and lymphocyte counts before and after SB drug administration.

The number of total white blood cells and monocytes in 24 consecutive advanced and recurrent cancer patients were recorded before and after SB administrations, as described in Materials and Methods. Patients were monitored for 10 days before the administrations and for 42 days after the administrations.
Figure 2. CD4⁺ T cell changes after SB anticancer drug administration.

The number of CD4⁺ T cells in 24 consecutive advanced and recurrent cancer patients were recorded before and after SB administrations as described in Materials and Methods. Patients were monitored for 10 days before administrations and for 42 days after administrations. The SB drug boosted the patient’s immune systems.

Figure 3. CD8⁺ T cell changes after SB anticancer drug administration.

The number of CD8⁺ T cell in 24 consecutive advanced and recurrent cancer patients were measured before and after SB administrations as described in Materials and Methods. Patients were monitored for 10 days before administrations and for 42 days after administrations. The SB drug boosted the patient’s immune systems.

Figure 4. NK cell changes after SB anticancer drug administration.
The number of CD8+ T cells in 24 consecutive advanced and recurrent cancer patients, were measured before and after SB administrations, as described in Materials and Methods. Patients were monitored for 10 days before administrations and for 42 days after administrations. The SB drug boosted the patient’s immune systems.

4. Discussion

Cancer cells weaken the immune system by spreading into the bone marrow and thus diminish its hematopoietic function. Surgical stress also can suppress the immune system and therefore the granulocyte function as well as numbers of lymphocytes are decreased after major surgery [10, 11]. Most anticancer drugs and radiation therapy produce cytotoxicities, not only in the cancer cells, but also in normal cells. That produces undesirable side effects, especially in immune functioning cells, which are severely depleted by bone marrow suppression. This results in severe infection as well as rapid cancer metastases.

Our data reveals that total white blood cell counts were not significantly changed, but monocyte counts were slightly decreased after SB administration. However, one of the other well-known natural anticancer drug studies using mistletoe reported that total white blood cell and monocyte counts were increased, probably due to its immunogenic lectin component [12]. Disrupted CD4 T cell percentages were normalized 10 days after the SB administration, and decreased cell counts were moderately increased to the normal level seen within the healthy Korean population [13]. Disrupted CD8 T cell percentages were also normalized after 10 days of SB administration, and the cell counts were increased significantly. These remained at the level of the healthy Korean population thereafter [13].

Our investigation on the initial effects of the SB anticancer drug on immune cells of cancer patients demonstrates normalized total white blood cells within 10 days after SB administration. Total lymphocyte counts were slightly increased initially. CD4 and CD8 T cell percentages were also normalized within 10 days after SB administration. CD4 T cell counts were slightly decreased, while CD8 T cell counts were substantially increased, so that patients’ immune systems returned to normal levels. CD16/56 NK cell percentages were normalized shortly after the administration of the SB drug with a moderate increase in the total cell count, giving patients an average status.

5. Conclusion

We believe that the SB drug is a good and effective cytoapoptotic anticancer drug that rejuvenates the immune system so that it can be combined with other kinds of immune activating vaccines [17]. One aspect of chemotherapeutic resistance is the inability of the chemotherapy to eliminate cancer stem cells (CSC). A another option is to use monoclonal antibodies to target these CSC’s. This has already been the subject of several studies [18-20]. This new research shows that there is a potential to combine conventional chemotherapy with SB administration for a synergistic and effective treatment that does not produce adverse reactions.

The SB anticancer drug normalized total white blood cell counts within 10 days, thus achieving normal total lymphocyte counts. CD4 and CD8 T cell percentages were also normalized within 10 days after SB administration. CD4 T cell counts were slightly increased, while CD8 T cell counts were substantially increased, so that patients’ immune systems returned to normal levels. CD16/56 NK cell percentages were normalized shortly after the administration of the SB drug with a moderate increase in the total cell count, giving patients an average status.

Compliance with Ethics

None of authors has conflict of interest related to our study.

References


